{"id":768998,"date":"2025-10-15T17:28:01","date_gmt":"2025-10-15T17:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=768998"},"modified":"2025-10-15T17:28:01","modified_gmt":"2025-10-15T17:28:01","slug":"depemokimab-market-insights-2034-ultralongacting-antiil5-biologic-for-severe-eosinophilic-asthma-and-crswnp-with-global-sales-forecast-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/depemokimab-market-insights-2034-ultralongacting-antiil5-biologic-for-severe-eosinophilic-asthma-and-crswnp-with-global-sales-forecast-by-delveinsight_768998.html","title":{"rendered":"Depemokimab Market Insights 2034: Ultra-Long-Acting Anti-IL-5 Biologic for Severe Eosinophilic Asthma and CRSwNP with Global Sales Forecast by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/10\/1760549331.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Depemokimab Market Insights 2034: Ultra-Long-Acting Anti-IL-5 Biologic for Severe Eosinophilic Asthma and CRSwNP with Global Sales Forecast by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/10\/1760549331.jpg\" alt=\"Depemokimab Market Insights 2034: Ultra-Long-Acting Anti-IL-5 Biologic for Severe Eosinophilic Asthma and CRSwNP with Global Sales Forecast by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Depemokimab Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Depemokimab market report provides a comprehensive analysis of GSK\u2019s ultra-long-acting IL-5 monoclonal antibody, Depemokimab (GSK3511294), positioning it as a transformative therapy for severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and other Type-2 inflammatory disorders.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s latest report, <em>&ldquo;<strong>Depemokimab Market Insights, Clinical Pipeline, and Sales Forecast 2034<\/strong>&rdquo;<\/em>, provides a comprehensive analysis of GSK&rsquo;s ultra-long-acting IL-5 monoclonal antibody, <strong>Depemokimab (GSK3511294)<\/strong>, positioning it as a transformative therapy for severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and other Type-2 inflammatory disorders. This report covers market trends, clinical developments, regulatory milestones, and projected sales in the seven major markets (7MM): United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Explore detailed sales forecasts, Phase III trial results, and global market opportunities for severe eosinophilic asthma and CRSwNP &ndash; <\/em><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/depemokimab-sale-forecast-and-market-analysis?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Depemokimab Sales Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Depemokimab Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Depemokimab is a <strong>monoclonal antibody targeting interleukin-5 (IL-5)<\/strong>, a key cytokine in Type-2 inflammation. Type-2 inflammation is associated with elevated <strong>blood eosinophil counts (BEC)<\/strong>, contributing to asthma exacerbations and nasal polyp formation. By inhibiting IL-5, Depemokimab reduces eosinophil survival and activation, providing durable symptom control and a potential reduction in hospitalization rates.<\/p>\n<p style=\"text-align: justify;\">A core differentiator of Depemokimab is its <strong>ultra-long-acting formulation<\/strong>, enabling <strong>twice-yearly dosing<\/strong>, compared to currently available IL-5 biologics that require more frequent administration (every 4&ndash;8 weeks). This dosing schedule enhances <strong>patient adherence, convenience, and overall treatment satisfaction<\/strong>, making it a highly competitive option in the <strong>respiratory biologics market<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Depemokimab Indications and Clinical Development<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Severe Eosinophilic Asthma<\/strong><\/p>\n<p style=\"text-align: justify;\">Depemokimab has demonstrated significant efficacy in <strong>SWIFT-1 and SWIFT-2 Phase III trials<\/strong>, showing:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>~54% reduction in annual severe exacerbation rates<\/strong> compared to placebo<\/li>\n<li>Improved lung function and asthma control scores<\/li>\n<li>A safety profile consistent with the IL-5 class, primarily <strong>tolerable GI and injection-site reactions<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Severe eosinophilic asthma remains a primary target population, with <strong>treatment-na&iuml;ve and treatment-experienced patients<\/strong> expected to benefit from the convenient twice-yearly administration. The <strong>SWIFT trials<\/strong> also included patients with overlapping Type-2 inflammatory conditions, enabling a multi-specialty commercial approach involving <strong>pulmonologists, allergists, and ENT specialists<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)<\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>ANCHOR-1 and ANCHOR-2 Phase III trials<\/strong> evaluated Depemokimab in adult patients with <strong>inadequately controlled CRSwNP<\/strong>. Key findings include:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Significant reduction in <strong>nasal polyp size<\/strong><\/li>\n<li>Improvements in <strong>nasal obstruction and patient-reported outcomes<\/strong><\/li>\n<li>Positive safety and tolerability profile<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">These results support CRSwNP as a <strong>secondary commercial indication<\/strong>, expanding the patient base for Depemokimab across respiratory comorbidities.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Depemokimab Emerging Indications<\/strong><\/p>\n<p style=\"text-align: justify;\">Depemokimab is also under investigation for other Type-2 inflammatory disorders, including:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Chronic Obstructive Pulmonary Disease (COPD)<\/strong><\/li>\n<li><strong>Churg-Strauss Syndrome (Eosinophilic Granulomatosis with Polyangiitis)<\/strong><\/li>\n<li><strong>Hypereosinophilic Syndrome (HES)<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Ongoing <strong>Phase III studies<\/strong> and <strong>registration trials<\/strong> (e.g., NCT07177339, NCT05263934, NCT05334368) aim to establish efficacy, safety, and long-term outcomes, potentially broadening Depemokimab&rsquo;s market footprint.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Learn how GSK&rsquo;s twice-yearly Anti-IL-5 biologic is poised to disrupt the respiratory biologics market &ndash; <\/em><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/depemokimab-sale-forecast-and-market-analysis?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Depemokimab Market Insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Depemokimab Regulatory Milestones<\/strong><\/p>\n<p style=\"text-align: justify;\">GSK has made significant progress in obtaining <strong>regulatory approvals<\/strong> for Depemokimab:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>US FDA<\/strong>: Biologics License Application (BLA) accepted for review in <strong>asthma and CRSwNP<\/strong><\/li>\n<li><strong>Health Canada<\/strong>: New Drug Submission (NDS) accepted for two indications<\/li>\n<li><strong>EU and Japan<\/strong>: Regulatory filings are underway, positioning Depemokimab for global launch<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The regulatory approvals for Depemokimab in <strong>adults and adolescents<\/strong> with Type-2 inflammation will expand the eligible patient pool and reinforce GSK&rsquo;s <strong>respiratory franchise<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Depemokimab Market Potential and Sales Forecast<\/strong><\/p>\n<p style=\"text-align: justify;\">According to DelveInsight&rsquo;s <strong>Depemokimab Market Forecast 2034<\/strong>, the therapy is expected to <strong>capture substantial market share<\/strong> in both asthma and CRSwNP due to:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Twice-yearly dosing convenience<\/strong><\/li>\n<li>Strong <strong>Phase III efficacy data<\/strong><\/li>\n<li>Favorable <strong>safety and tolerability profile<\/strong><\/li>\n<li>Growing <strong>specialist referrals for Type-2 inflammatory disorders<\/strong><\/li>\n<li>Increasing <strong>payers&rsquo; focus on cost-effective biologics that reduce exacerbations and hospitalizations<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Estimated 7MM Depemokimab Market Uptake<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>United States<\/strong>: Projected to lead sales due to a high prevalence of severe eosinophilic asthma and reimbursement-friendly environment<\/li>\n<li><strong>EU4 (Germany, France, Italy, Spain)<\/strong>: Moderate uptake expected, accelerated by adoption in specialty centers<\/li>\n<li><strong>United Kingdom &amp; Japan<\/strong>: Growing adoption driven by positive guideline endorsements<\/li>\n<li><strong>Emerging Markets<\/strong>: Asia-Pacific and Latin America projected to experience <strong>rapid growth<\/strong> if reimbursement is secured, supported by the <strong>ultra-long-acting dosing schedule<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Depemokimab Competitive Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">Depemokimab competes in the <strong>anti-IL-5 biologics market<\/strong>, alongside:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Mepolizumab (Nucala, GSK\/AstraZeneca)<\/strong><\/li>\n<li><strong>Reslizumab (Cinqair, Teva)<\/strong><\/li>\n<li><strong>Benralizumab (Fasenra, AstraZeneca)<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key differentiators include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Twice-yearly dosing vs every 4&ndash;8 weeks for competitors<\/strong><\/li>\n<li><strong>High potency IL-5 inhibition<\/strong> targeting both exacerbations and nasal polyp formation<\/li>\n<li><strong>Broad adoption potential across pulmonology, allergy, and ENT specialties<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>See how Depemokimab&rsquo;s adoption and competitive positioning could impact your portfolio in the US, EU4, UK, Japan, and emerging markets &ndash; <\/em><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/depemokimab-sale-forecast-and-market-analysis?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Depemokimab Competitive Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Market trends<\/strong><strong> supporting Depemokimab uptake:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Rising prevalence of <strong>Type-2 inflammatory disorders<\/strong><\/li>\n<li>Growing awareness of <strong>comorbid asthma and CRSwNP<\/strong><\/li>\n<li>Increasing demand for <strong>convenient, long-acting biologics<\/strong><\/li>\n<li>Payer preference for therapies that <strong>reduce hospitalizations and overall treatment costs<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Drivers of Depemokimab Growth<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li><strong>Patient and Physician Adoption<\/strong>: The simplified <strong>twice-yearly dosing<\/strong> and demonstrated efficacy are expected to drive high new-patient starts and switching from existing biologics.<\/li>\n<li><strong>Robust Clinical Data<\/strong>: Phase III results from SWIFT and ANCHOR trials provide strong evidence of efficacy in both primary indications.<\/li>\n<li><strong>Regulatory Momentum<\/strong>: Acceptance of BLA and NDS submissions in major markets accelerates the likelihood of early commercial adoption.<\/li>\n<li><strong>Global Reach<\/strong>: Launch plans in the US, EU, Japan, and emerging markets expand revenue potential.<\/li>\n<li><strong>Multi-Indication Potential<\/strong>: Opportunities in COPD, Churg-Strauss syndrome, and HES increase Depemokimab&rsquo;s long-term market value.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Stay ahead with the latest updates on Depemokimab, anti-IL-5 biologics, and other Type-2 inflammation therapies &ndash; <\/em><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/depemokimab-sale-forecast-and-market-analysis?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Depemokimab Drug Sales<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Depemokimab Market Barriers and Risks<\/strong><\/p>\n<p style=\"text-align: justify;\">Despite its promise, Depemokimab faces several challenges:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Regulatory review timelines<\/strong> and potential follow-up requests could delay market entry<\/li>\n<li><strong>Pricing and reimbursement negotiations<\/strong> in high-cost biologic markets<\/li>\n<li><strong>Competition from established anti-IL-5 agents<\/strong> and other Type-2 biologics (IL-4\/13 inhibitors, anti-IgE therapies)<\/li>\n<li><strong>Post-marketing safety surveillance<\/strong> required for ultra-long-acting biologics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Addressing these barriers will require strategic <strong>payer engagement, real-world evidence generation, and physician education<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Opportunities in the Depemokimab Market<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Expansion into pediatric and adolescent populations<\/strong> with Type-2 inflammation<\/li>\n<li><strong>Combination therapies<\/strong> addressing comorbid asthma and CRSwNP<\/li>\n<li>Development of <strong>real-world evidence programs<\/strong> demonstrating cost savings and quality-of-life improvements<\/li>\n<li>Potential <strong>late-stage emerging indications<\/strong>, including HES and COPD, may increase lifetime value per patient<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Depemokimab Mechanism of Action (MoA)<\/strong><\/p>\n<p style=\"text-align: justify;\">Depemokimab selectively binds to <strong>IL-5<\/strong>, inhibiting eosinophil survival and activation. IL-5 is a <strong>key driver of Type-2 inflammation<\/strong>, contributing to:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Airway hyperresponsiveness and asthma exacerbations<\/li>\n<li>Nasal polyp growth in CRSwNP<\/li>\n<li>Organ damage in eosinophilic syndromes<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">By targeting IL-5 with <strong>high potency and extended half-life<\/strong>, Depemokimab offers superior <strong>mechanistic efficacy<\/strong> over competing therapies and supports durable clinical benefits.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Book a Consultation with Our Analysts &ndash; Understand Depemokimab&rsquo;s clinical differentiation, regulatory milestones, and market potential to guide strategic decisions &ndash; <\/em><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/depemokimab-sale-forecast-and-market-analysis?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Depemokimab Clinical Updates<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Depemokimab Strategic Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">GSK&rsquo;s strategic focus for Depemokimab includes:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Global launch and commercial partnerships<\/strong> across the US, EU, Canada, Japan, and emerging markets<\/li>\n<li><strong>Specialist education and patient support programs<\/strong> to maximize adherence and persistence<\/li>\n<li><strong>Health-economic and real-world evidence generation<\/strong> to support reimbursement<\/li>\n<li><strong>Lifecycle management<\/strong> through late-stage indications and combination therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">With these initiatives, Depemokimab is positioned to become a <strong>leading therapy in the respiratory biologics market<\/strong>, with significant potential to <strong>expand GSK&rsquo;s Type-2 inflammatory disease franchise<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Depemokimab represents a <strong>first-in-class ultra-long-acting IL-5 biologic<\/strong> with twice-yearly dosing<\/li>\n<li><strong>Phase III trials (SWIFT, ANCHOR)<\/strong> demonstrate robust efficacy in <strong>severe eosinophilic asthma and CRSwNP<\/strong><\/li>\n<li>Regulatory submissions underway in <strong>US, Canada, EU, and Japan<\/strong>, enabling global commercial rollout<\/li>\n<li>Strategic differentiation via <strong>mechanistic targeting, long-acting dosing, and multi-specialty adoption<\/strong> positions Depemokimab as a market leader<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a global market research and consulting firm providing <strong>comprehensive insights into pharmaceutical, biotech, and healthcare markets<\/strong>. Our in-depth analyses cover <strong>market trends, competitive landscapes, clinical developments, regulatory pathways, and sales forecasts<\/strong>, helping industry stakeholders make informed strategic decisions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=depemokimab-market-insights-2034-ultralongacting-antiil5-biologic-for-severe-eosinophilic-asthma-and-crswnp-with-global-sales-forecast-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/competitive-intelligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/competitive-intelligence-services<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=depemokimab-market-insights-2034-ultralongacting-antiil5-biologic-for-severe-eosinophilic-asthma-and-crswnp-with-global-sales-forecast-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Depemokimab Market Depemokimab market report provides a comprehensive analysis of GSK\u2019s ultra-long-acting IL-5 monoclonal antibody, Depemokimab (GSK3511294), positioning it as a transformative therapy for severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and other Type-2 inflammatory disorders. DelveInsight&rsquo;s latest &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/depemokimab-market-insights-2034-ultralongacting-antiil5-biologic-for-severe-eosinophilic-asthma-and-crswnp-with-global-sales-forecast-by-delveinsight_768998.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-768998","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/768998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=768998"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/768998\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=768998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=768998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=768998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}